|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-7-27
|
|
pubmed:abstractText |
We aimed to utilize genome-wide expression analysis to identify molecular pathways that may contribute to endometrial cancer resistance to doxorubicin (DOX) and that also represent therapeutic targets to increase DOX sensitivity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1097-6868
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
203
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
158.e1-40
|
|
pubmed:meshHeading |
pubmed-meshheading:20444440-Antibiotics, Antineoplastic,
pubmed-meshheading:20444440-Cell Line, Tumor,
pubmed-meshheading:20444440-Cell Proliferation,
pubmed-meshheading:20444440-Doxorubicin,
pubmed-meshheading:20444440-Drug Delivery Systems,
pubmed-meshheading:20444440-Drug Resistance, Neoplasm,
pubmed-meshheading:20444440-Endometrial Neoplasms,
pubmed-meshheading:20444440-Endometrium,
pubmed-meshheading:20444440-Female,
pubmed-meshheading:20444440-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20444440-Genes, Neoplasm,
pubmed-meshheading:20444440-Genome,
pubmed-meshheading:20444440-Humans,
pubmed-meshheading:20444440-Microbial Sensitivity Tests,
pubmed-meshheading:20444440-Pharmacogenetics,
pubmed-meshheading:20444440-Probability,
pubmed-meshheading:20444440-RNA,
pubmed-meshheading:20444440-Sensitivity and Specificity
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin.
|
|
pubmed:affiliation |
Department of Women's Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33629, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
